Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Income Statement
Earnings Waterfall
Supernus Pharmaceuticals Inc
Revenue
|
607.5m
USD
|
Cost of Revenue
|
-83.8m
USD
|
Gross Profit
|
523.7m
USD
|
Operating Expenses
|
-508.8m
USD
|
Operating Income
|
14.9m
USD
|
Other Expenses
|
-13.6m
USD
|
Net Income
|
1.3m
USD
|
Income Statement
Supernus Pharmaceuticals Inc
Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
12
N/A
|
21
+75%
|
50
+140%
|
72
+42%
|
93
+29%
|
112
+21%
|
118
+5%
|
135
+14%
|
148
+9%
|
163
+11%
|
179
+10%
|
196
+10%
|
215
+10%
|
228
+6%
|
253
+11%
|
276
+9%
|
302
+9%
|
335
+11%
|
359
+7%
|
381
+6%
|
409
+7%
|
404
-1%
|
409
+1%
|
408
0%
|
393
-4%
|
402
+2%
|
424
+5%
|
477
+12%
|
520
+9%
|
556
+7%
|
571
+3%
|
564
-1%
|
580
+3%
|
601
+4%
|
630
+5%
|
659
+5%
|
667
+1%
|
669
+0%
|
634
-5%
|
611
-4%
|
608
-1%
|
|
Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
Cost of Revenue |
(1)
|
(2)
|
(3)
|
(5)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(9)
|
(10)
|
(11)
|
(12)
|
(13)
|
(14)
|
(15)
|
(15)
|
(16)
|
(16)
|
(15)
|
(15)
|
(16)
|
(16)
|
(17)
|
(17)
|
(17)
|
(22)
|
(38)
|
(53)
|
(63)
|
(80)
|
(77)
|
(75)
|
(78)
|
(74)
|
(81)
|
(87)
|
(93)
|
(94)
|
(87)
|
(84)
|
|
Gross Profit |
11
N/A
|
19
+80%
|
47
+147%
|
67
+43%
|
87
+29%
|
106
+21%
|
111
+6%
|
127
+14%
|
139
+9%
|
154
+11%
|
169
+10%
|
185
+10%
|
203
+9%
|
216
+6%
|
239
+11%
|
261
+10%
|
287
+10%
|
320
+11%
|
344
+7%
|
366
+7%
|
394
+7%
|
388
-1%
|
393
+1%
|
392
0%
|
376
-4%
|
385
+2%
|
403
+5%
|
439
+9%
|
468
+7%
|
493
+5%
|
491
0%
|
488
-1%
|
505
+3%
|
523
+4%
|
557
+6%
|
578
+4%
|
580
+0%
|
576
-1%
|
541
-6%
|
524
-3%
|
524
+0%
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(73)
|
(77)
|
(85)
|
(89)
|
(92)
|
(93)
|
(99)
|
(109)
|
(118)
|
(131)
|
(138)
|
(140)
|
(149)
|
(151)
|
(160)
|
(180)
|
(188)
|
(205)
|
(219)
|
(227)
|
(249)
|
(250)
|
(248)
|
(244)
|
(228)
|
(233)
|
(240)
|
(260)
|
(286)
|
(335)
|
(345)
|
(365)
|
(396)
|
(449)
|
(505)
|
(560)
|
(534)
|
(526)
|
(520)
|
(493)
|
(509)
|
|
Selling, General & Administrative |
(56)
|
(60)
|
(67)
|
(70)
|
(73)
|
(75)
|
(78)
|
(84)
|
(89)
|
(95)
|
(98)
|
(101)
|
(106)
|
(109)
|
(118)
|
(133)
|
(138)
|
(147)
|
(152)
|
(152)
|
(160)
|
(164)
|
(165)
|
(165)
|
(158)
|
(160)
|
(160)
|
(174)
|
(192)
|
(213)
|
(242)
|
(259)
|
(283)
|
(311)
|
(342)
|
(383)
|
(377)
|
(372)
|
(359)
|
(329)
|
(336)
|
|
Research & Development |
(17)
|
(17)
|
(18)
|
(19)
|
(20)
|
(19)
|
(21)
|
(26)
|
(29)
|
(36)
|
(40)
|
(39)
|
(43)
|
(42)
|
(42)
|
(47)
|
(50)
|
(59)
|
(68)
|
(76)
|
(89)
|
(86)
|
(83)
|
(79)
|
(69)
|
(73)
|
(78)
|
(78)
|
(76)
|
(91)
|
(85)
|
(87)
|
(91)
|
(77)
|
(78)
|
(78)
|
(75)
|
(75)
|
(83)
|
(86)
|
(92)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(9)
|
(16)
|
(20)
|
(24)
|
(24)
|
(30)
|
(45)
|
(59)
|
(74)
|
(83)
|
(82)
|
(81)
|
(82)
|
(82)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(11)
|
6
|
6
|
7
|
(16)
|
(25)
|
(25)
|
1
|
3
|
3
|
4
|
2
|
|
Operating Income |
(62)
N/A
|
(57)
+7%
|
(38)
+33%
|
(22)
+43%
|
(5)
+76%
|
12
N/A
|
12
+1%
|
18
+48%
|
21
+16%
|
23
+12%
|
31
+34%
|
46
+47%
|
54
+19%
|
65
+19%
|
79
+22%
|
82
+3%
|
100
+22%
|
114
+15%
|
124
+8%
|
139
+12%
|
144
+4%
|
139
-4%
|
145
+5%
|
148
+2%
|
149
+1%
|
152
+2%
|
162
+7%
|
179
+10%
|
182
+2%
|
158
-13%
|
146
-7%
|
123
-16%
|
108
-12%
|
75
-31%
|
52
-30%
|
18
-66%
|
46
+158%
|
49
+7%
|
20
-59%
|
30
+47%
|
15
-50%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
(21)
|
(21)
|
(11)
|
(4)
|
(2)
|
(2)
|
(1)
|
(1)
|
(0)
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
3
|
2
|
1
|
0
|
(1)
|
2
|
2
|
(1)
|
0
|
(2)
|
(5)
|
(1)
|
(3)
|
(4)
|
(5)
|
(9)
|
6
|
8
|
13
|
17
|
8
|
8
|
8
|
9
|
|
Non-Reccuring Items |
(10)
|
(11)
|
(10)
|
(11)
|
(3)
|
(3)
|
(3)
|
(2)
|
(2)
|
(1)
|
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(7)
|
(8)
|
0
|
0
|
0
|
(22)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(20)
|
|
Total Other Income |
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(2)
|
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(4)
|
(3)
|
(2)
|
(1)
|
(1)
|
(2)
|
(3)
|
(4)
|
(5)
|
(5)
|
(5)
|
0
|
0
|
4
|
3
|
(4)
|
(4)
|
(8)
|
(7)
|
(4)
|
(4)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
|
Pre-Tax Income |
(92)
N/A
|
(89)
+3%
|
(59)
+34%
|
(37)
+37%
|
(10)
+72%
|
6
N/A
|
6
-8%
|
12
+118%
|
15
+22%
|
19
+29%
|
27
+42%
|
42
+56%
|
50
+20%
|
62
+22%
|
77
+25%
|
81
+5%
|
101
+24%
|
116
+15%
|
123
+6%
|
137
+11%
|
140
+3%
|
133
-5%
|
142
+7%
|
145
+2%
|
148
+2%
|
152
+3%
|
157
+3%
|
170
+8%
|
169
-1%
|
151
-11%
|
135
-11%
|
111
-18%
|
73
-34%
|
77
+5%
|
57
-26%
|
28
-51%
|
61
+119%
|
55
-9%
|
27
-52%
|
37
+39%
|
3
-92%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
42
|
41
|
35
|
27
|
(23)
|
(34)
|
(33)
|
(27)
|
(28)
|
(29)
|
(30)
|
(37)
|
(40)
|
(34)
|
(36)
|
(39)
|
(41)
|
(42)
|
(39)
|
(34)
|
(29)
|
(20)
|
(4)
|
0
|
10
|
0
|
(3)
|
17
|
(11)
|
(1)
|
|
Income from Continuing Operations |
(92)
|
(89)
|
(59)
|
(37)
|
(11)
|
5
|
5
|
11
|
14
|
18
|
26
|
84
|
91
|
97
|
104
|
58
|
67
|
83
|
97
|
109
|
111
|
103
|
105
|
106
|
113
|
116
|
118
|
129
|
127
|
111
|
100
|
82
|
53
|
73
|
58
|
38
|
61
|
52
|
43
|
26
|
1
|
|
Net Income (Common) |
(92)
N/A
|
(89)
+3%
|
(59)
+34%
|
(37)
+37%
|
(11)
+71%
|
5
N/A
|
5
-15%
|
11
+140%
|
14
+29%
|
18
+29%
|
26
+44%
|
84
+224%
|
91
+9%
|
97
+6%
|
104
+7%
|
58
-44%
|
57
-1%
|
74
+28%
|
87
+18%
|
99
+14%
|
111
+12%
|
103
-7%
|
105
+2%
|
106
+1%
|
113
+7%
|
116
+3%
|
118
+2%
|
129
+9%
|
127
-2%
|
111
-12%
|
100
-10%
|
82
-18%
|
53
-35%
|
73
+37%
|
58
-22%
|
38
-35%
|
61
+61%
|
52
-14%
|
43
-17%
|
26
-41%
|
1
-95%
|
|
EPS (Diluted) |
-2.65
N/A
|
-2.13
+20%
|
-1.38
+35%
|
-0.86
+38%
|
-0.26
+70%
|
0.13
N/A
|
0.1
-23%
|
0.2
+100%
|
0.28
+40%
|
0.35
+25%
|
0.5
+43%
|
1.61
+222%
|
1.76
+9%
|
1.83
+4%
|
1.95
+7%
|
1.08
-45%
|
1.07
-1%
|
1.36
+27%
|
1.6
+18%
|
1.82
+14%
|
2.05
+13%
|
1.91
-7%
|
1.95
+2%
|
1.97
+1%
|
2.1
+7%
|
2.17
+3%
|
2.21
+2%
|
2.41
+9%
|
2.36
-2%
|
2.07
-12%
|
1.85
-11%
|
1.51
-18%
|
0.98
-35%
|
1.19
+21%
|
0.93
-22%
|
0.68
-27%
|
0.98
+44%
|
0.83
-15%
|
0.79
-5%
|
0.46
-42%
|
0.02
-96%
|